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Conformational disorders1. Introduction
Conformational diseases, which include Alzheimer's disease and
Parkinson's disease, are the result of the accumulation of intracellular
dysfunctional proteins, such as amyloid-beta and alpha-synuclein
(Jucker and Walker, 2011). Abnormal prion protein (PrPSc) has also
been shown to be a pathogenic protein, which is formed by conforma-
tional changes to the native cellular prion protein (PrPC) (Weissmann
et al., 2002). The molecular mechanisms of conversion remain poorly
understood, although drug discovery studies have focused on the con-
version process fromPrPC andPrPSc. A variety of drugs have been report-
ed to reduce PrPSc levels by halting the conversion process as described
below: acridines including quinacrine (Vogtherr et al., 2003); anti-PrP
antibodies including D18 (Peretz et al., 2001), 6H4 (Enari et al., 2001)
and ICSM38 (White et al., 2003); polyanions including pentosane
polysulfate (PPS) (Doh-ura et al., 2004; Priola and Caughey, 1994); dex-
tran sulfate (Caughey and Raymond, 1993) and HM2602 (Adjou et al.,icrobiology and Immunology,
ces, 1-12-4 Sakamoto, Nagasaki
. This is an open access article under2003); the polyene antibiotics including amphotericin B (Mange et al.,
2000) and ﬁlipin (Marella et al., 2002); the others including suramin
(Gilch et al., 2001), Congo-Red (Caughey and Race, 1992), Cpd B
(Kawasaki et al., 2007), GN8 (Kuwata et al., 2007) and luminescent-con-
jugated polythiopherenes (LCPs) (Herrmann et al., 2015). Other studies
have focused on the intracellular proteolytic system, such as autophagy
of insoluble proteins, because the PrPSc complex and the PrP oligomer
may have toxic effects on the cell (Aguzzi and Calella, 2009). In vitro
and in vivo studies using compounds such as lithium (Heiseke et al.,
2009), trehalose (Aguib et al., 2009), rapamycin (Ishibashi et al., 2015),
tamoxifen (Marzo et al., 2013), FK506 (Nakagaki et al., 2013), IU-1
(Homma et al., 2015), have reported anti-prion effects. Among them,
PPS, Cpd B, LCPs, and FK506 signiﬁcantly prolong survival periods in
mice inoculated with RML or FK-1 prion strains (Doh-ura et al., 2004;
Herrmann et al., 2015; Kawasaki et al., 2007; Nakagaki et al., 2013). Re-
cently, it especially has been reported that Anle138b has potent and
broad spectrum activity for different protein aggregation diseasemodels
(Wagner et al., 2013). Studies have continued to identify suitable com-
pounds for treating the diseases, although none have provided any evi-
dence of beneﬁts against human prion disease, even though some
were tested in clinical trials (Tsuboi et al., 2009; Haik et al., 2014).
The structure-based drug discovery (SBDD) using computer simula-
tion was recently facilitated to develop effective chemical compounds.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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has successfully identiﬁed compounds for treating several diseases,
such as nelﬁnavir (Kaldor et al., 1997) and amprenavir (Highleyman,
1999) for AIDS; zanamivir for inﬂuenza (McCauley, 1999); celecoxib
(Stratton and Alberts, 2002) and rofecoxib (Mardini and FitzGerald,
2001) as cyclooxygenase 2 inhibitors; antibacterial agents (Simmons
et al., 2010); Ras inhibitor for human cancer (Shima et al., 2013).
SBDD has also been used in prion disease, showing that Cp-60, −62
compounds that mimic the dominant negative PrPC mutant inhibit
PrPSc formation (Perrier et al., 2000) and that GN8 strongly stabilises
normal conformation by binding to a speciﬁc region in PrPC, which sup-
presses PrPSc production and prolongs survival of prion-infected mice
(Kuwata et al., 2007). Furthermore, other small compounds that target
the same position as the interaction between GN8 and PrPC have been
discovered by virtual screeningwhich used original docking simulation,
and those compounds reduced PrPSc levels in RML prion-infected cells
(Hyeon et al., 2015). In this study, we performed original docking simu-
lations, termed Nagasaki University Docking Engine (NUDE) for PrPC
conformation and small compounds in a large chemical compound da-
tabase using the DEGIMA supercomputer system. Binding interactions
were analysed using the fragment molecular orbital (FMO) method to
identify novel anti-prion drugs. Following virtual screening, we tested
the ability of candidate compounds to bind to PrPC using surface plas-
mon resonance (SPR) analysis. The thermal shift assay (TSA) was used
to determine whether the compounds inﬂuenced thermal change-de-
pendent PrPC stabilisation. We also evaluated the anti-prion effect of
compounds using persistently prion-infected cells and mice, which re-
vealed novel therapeutic candidates.
2. Materials and methods
2.1. Regents and antibodies
All candidate compounds (NPR-015,−050,−053,−056 and−065)
identiﬁed by in silico calculation were purchased from ASINEX (Supple-
mentary Fig. S8). GN8 was gifted from Prof. Kuwata (Gifu University)
and served as the positive anti-prion control drug (Kuwata et al., 2007).
These compoundswere completely dissolved in 100% dimethyl sulfoxide
(DMSO) and adjusted to 10mMas stock solution. Stock solutions of com-
pound were diluted in sterile water, culture medium or phosphate buff-
ered saline (PBS) to perform the several assay in this study. Antibodies
speciﬁc for PrP (Santa Cruz Biotechnology, M20; SPI-Bio, SAF61), Iba-1
(WAKO, 019-19741 for IHC and 016-20001 for WB) and β-actin (MBL)
were purchased from the indicated vendors. Horseradish peroxidase-
conjugated anti-goat (Jackson ImmunoResearch) and anti-mouse (GE
Healthcare Life Sciences) IgG antibodies were used for immunoblotting.
2.2. In silico screening
To obtain potential candidate anti-prion compounds, we performed
a docking simulation using an original chemical compound library that
included approximately 210,000 compounds. The three-dimensional
structure of each compound was produced by Open Babel software
(O'Boyle et al., 2011), which was followed by energy minimisation
using GAFF force ﬁeld (Wang et al., 2004). In our docking simulation, a
structure of the globular domain of human PrPC (124–230th amino
acid residues) was used as a receptor, whose atomic coordinates were
prepared from the Nuclear Magnetic Resonance (NMR) structure
(Biljan et al., 2012) (Protein Data Band code: 2LSB). A cubic space
(64 × 64 × 64 Å) was used as the search region for the docking simula-
tion, and binding with the whole surface of the target protein was ex-
amined. We employed an original docking simulation program
designed as a Graphics ProcessingUnit (GPU). In this study, theDEGIMA
(DEstination for Gpu Intensive MAchine) supercomputer from the Na-
gasaki Advanced Computing Center, which was constructed with
more than 100 GPUs, was used for the docking simulation.2.3. Fragment molecular orbital calculation
To analyse binding conformations obtained from the docking simu-
lation, FMO calculations (Kitaura et al., 1999) were performed. To pre-
pare reliable atomic coordinates for the FMO calculations, hydrogen
atoms were added to the docking structure and the N-terminal of the
G124 was capped by\\COCH3. An energy minimisation with classical
force ﬁelds (AMBER99SB (Hornak et al., 2006) and GAFF (Wang et al.,
2004)) was performed using the AMBER 10 program (Case, 2008),
and the energy minimised structure was used for the FMO calculations.
Amino acid residues and compounds were treated as a single fragment,
except for C179 and C214, which were merged into one fragment, be-
cause they have a disulﬁde bond. Interaction energies were calculated
at the Hartree–Fock (HF) level and second-orderMøller–Plesset pertur-
bation (MP2) level with resolution of the identity approximation
(Ishikawa and Kuwata, 2009) using cc-pVDZ basis set (Dunning,
1989). In this study, the FMO calculations were performed using the
PAICS program (Ishikawa et al., 2009).
2.4. Surface plasmon resonance (SPR) analysis
Interactions between recombinant PrP and compounds were evalu-
ated using a Biacore T200 system (GE Healthcare) as previously de-
scribed (Nakagaki et al., 2013). Human or mouse PrP (23−231) was
synthesised by Escherichia coli in a protein expression system using
the pET vector, and the protein was puriﬁed by imidazole in a NTA col-
umn as previously described (Atarashi et al., 2011). The recombinant
PrP solutions were diluted to 10 μg/mL with running buffer (10 mM
HEPES, pH 7.4 containing 150mMNaCl, 0.05% Tween20 [Sigma Aldrich]
and 5% DMSO), and the ligandswere immobilised on a CM5 sensor chip
(GE, BR-100,530) using an amine coupling kit (GE, BR-1000-50). Immo-
bilisation of PrP was performed with an average of 2000 RUs. Com-
pounds of various concentrations were diluted with the same running
buffer and evaluated by injecting them sequentially for 2 min at a ﬂow
rate of 30 mL/min, after which the running buffer alone was injected
for a further 20 min at the same ﬂow rate to wash out the bound com-
pounds. Datawere corrected using a blank sensor chip as a control. Each
compoundwas dissolved in DMSO and diluted to 5%with running buff-
er (Nakagaki et al., 2013).
2.5. Cell cultures
Mouse neuroblastomaNeuro 2a cells were obtained from the Amer-
ican Type Culture Collection (CCL 131). N2a-58 cells are established
from N2a cells overexpressing PrPC and integrating mouse prnp gene
in Neuro 2a cells. N2a-FK cells established from N2a-58 cells were in-
fected with a mouse-adapted Gerstmann–Sträussler–Scheinker strain,
Fukuoka-1, as previously described (Ishibashi et al., 2015, Ishibashi et
al., 2011). N2a-22L cells were established from N2a-58 cells infected
with a mouse-adapted scrapie 22L strain as previously described
(Homma et al., 2015, Homma et al., 2014a; Nishida et al., 2000). The
above cells were grown at 37 °C in 5% CO2 in Dulbecco's-modiﬁed
Eagle's medium (Wako) containing 4500 mg/mL glucose, 10% heat-
inactivated fetal bovine serum, 100 units/mL penicillin and 100 μg/mL
streptomycin (Nakarai Tesque). Cell viability was determined by
counting the living cells with Luna automatic cell counter instrument
(Logos Biosystems) and cell form was visualised by a microscope.
2.6. Immunobloting
Immunoblottingwas performed as previously described (Homma et
al., 2014b). For PrPSc detection, the lysates were digestedwith 20 μg/mL
proteinase K (PK;Nakarai Tesuque) at 37 °C for 30min. After addition of
SDS-sample buffer, the samples were applied to 15% SDS-PAGE gel and
were subsequently transferred to a PVDF membrane. To detect PrPSc,
M20 served as the primary antibody (1:1000) and anti-goat IgG-HRP
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using the Chemi-Lumi One (Nakarai Tesque) or ECL prime Western
Blotting Detection Kit (GE Healthcare). Band intensities were quantiﬁed
using ImageJ software (National Institutes of Health).
2.7. Immunoﬂuorescence analysis
In the prion-infected cells, immunoﬂuorescence staining was per-
formed as previously described (Homma et al., 2014b; Ishibashi et al.,
2015). Cells were treated with DMSO or 10 μM GN8 and NPRs for 48 h
in a chamber slide (BD Falcon). The cells were then washed twice in
PBS followed by ﬁxation with 4% formaldehyde for 30 min at room tem-
perature. After permeabilisation using 0.5% Triton X-100, the slides were
incubated in 5% skim milk for 1 h at room temperature. For PrPSc detec-
tion, the slides were incubated with 3 M guanidine thiocyanate for
5 min at room temperature. The cells were then incubated overnight at
4 °C in a SAF61-speciﬁc primary antibody (1:200) to detect PrPSc, follow-
ed by Alexa Fluor® 488-conjugated anti-mouse IgG (Invitrogen) (1:500)
for 1 h at 37 °C. Nuclei were stained with Vectashield mounting medium
containing DAPI (Vector Laboratories). All images were visualised using a
confocal laser-scanning microscope LSM 700 (Carl Zeiss).
2.8. Fluorescence-based thermal shift assay (F-TSA)
Fluorescence-based thermal shift assay was used to measure interac-
tions between recombinant human PrP and compounds, which were re-
vealed as temperature changes. These changes were detected using a
LightCycler® 480 system (Roche Diagnostics) and SYPRO orange (Life
Technologies), which has a maximum excitation at 470 nm and maxi-
mum emission at 570 nm. The reaction mixture was as follows: 100 μg/
mL recombinant PrP, 150 mM NaCl, 25 mM PIPES (pH 7.0) and 1000-
fold diluted SYPRO orange with or without 10 μM compounds in a 96-
well white plate (Roche Diagnostics). PrP stabilisation was evaluated by
measuring optical density at each temperature. The temperature was
gradually increased from 37 °C to 90 °C and ﬂuorescence scanning was
continuouslymeasured in 1-°C increments using the LightCycler® 480 in-
strumentwith awavelengthﬁlter of 483/610 nm. Theﬂuorescence inten-
sity from each protein dissociation curve was plotted for each thermal
point and ﬁtted to the Boltzmann sigmoidal equation using Origin 8.5
software. Each Tm (melting temperature) value was calculated from the
maximum value of the ﬁrst derivative curve of themelting curve, respec-
tively. The mean ± standard deviation (SD) obtained from results of at
least three experiments was considered for data analysis.
2.9. Protein aggregation assay
Protein aggregation in cells was evaluated using the ProteoStat®
Aggresome Detection Kit (Enzo Life Science). Proteostat selectively in-
teracts with proteins that have a β-sheet-rich structure similar to an
aggresome formation and has a maximum excitation at 500 nm and
maximum emission at 600 nm as ﬂuorescence dye. All kit reagents
and components were prepared according to the manufacturer's in-
structions. After treating cells with 10-μM GN8 or NPRs compounds
for 48 h, the cells were washed with PBS and permeabilised with 0.5%
Triton-X-100 containing 3 mM EDTA for 30 min on ice. After washing
with PBS, the cells were incubated for 30 min at room temperature in
the dark with a dual detection reagent (1:2000 Proteostat, 1:1000
Hoechst 33342 for nuclei staining). The proteostat-positive cells were
then observed using a LSM 700 confocal microscope.
2.10. In vivo infection experiments
Four-week-old ddYmale mice were purchased from SLC (Hamama-
tsu, Japan) and were intracerebrally inoculated with 20 μL of a 10−1 di-
lution of brain homogenate prepared from mice terminally infected
with the FK-1 strain. The compounds were dissolved in normal salinecontaining 0.25% DMSO, and the mice were intraperitoneally adminis-
tered 1.0 mg compound/kg/day every other day. As a control, age- and
strain-matchedmicewere intraperitoneally inoculated with normal sa-
line containing 0.25%DMSO.Miceweremonitored every other day until
the terminal stage of disease or until sacriﬁced. Clinical onset was de-
ﬁned as the presence of two or more symptoms: greasy and/or yellow-
ish hair, hunchback, weight loss, yellow pubic hair, ataxic gait and non-
parallel hind limbs. Themicewere sacriﬁced at clinical onset (110 d.p.i.)
or terminal stage and the brains and spleens were removed. The right
hemisphere of the brains and a section of spleenswere immediately fro-
zen and homogenised at 20% (weight/volume) in PBS. For immunoblot-
ting analysis, total proteins were extracted by mixing with an equal
amount of 2× lysis buffer (300 mM NaCl, 1% Triton-X-100, 1% sodium
deoxycholate and 100 mM Tris-HCl; pH 7.5). The remaining brains
and spleens were ﬁxed in 10% neutral-buffered formalin.
2.11. Ethics statement
All animal experimentswere approved by the Committee on the An-
imal Care and Use Committees of the Nagasaki University. All animals
were cared for in accordance with the Guidelines for Animal Experi-
mentation of Nagasaki University.
2.12. Pathological analysis
The ﬁxed tissues were embedded in parafﬁn and sectioned into
3 μm-thick sections. To evaluate spongiform changes, the sections
were stained with hematoxylin (WAKO, 131-09665) and eosin
(WAKO, 056-06722). For Iba-1 staining, after deparafﬁnisation and re-
hydration, the sections were boiled in Target Retrieval Solution, Citrate
pH 6 (DAKO, S2369) for 20 min for antigen retrieval. The blocked sec-
tions were treated with 0.3% hydrogen peroxidase (WAKO, 086-
07445) in methanol (Hayashi Pure Chemical, 130-02069) for 30 min
to inactivate endogenous peroxidase and then incubatedwith 3% nonfat
dry milk (Megmilk Snow Brand, FA-08) in Tris-buffered saline contain-
ing 0.1% Tween 20 (TBST) for 60min at room temperature. The blocked
sections were incubated with a primary antibody (anti-Iba-1 antibody,
WAKO, 019-19741) overnight at room temperature, followed by envi-
sion polymer horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG (DAKO, K4002) for 60 min at room temperature. Immunostaining
was visualised using 3, 3-diaminobenzidine (DAB; Dojindo Lab, D006).
The hydrolytic autoclaving and formic acid method for PrPSc staining
have been previously described (Ishibashi et al., 2012).
2.13. Statistical analysis
Results in the graph represent mean ± SD from at least three inde-
pendent experiments. Statistical analysis of all data was performed
using Statcel 2 from Excel and GraphPad Prism software. The Student's
t-test was used to compare between two groups, and one- or two-way
analysis of variance followed by the Tukey–Kramer test was used for
multiple comparisons. The log-rank test was used to analyse themortal-
ity in prion-infected mice.
3. Results
3.1. In silico screening
Docking scores, which are related to the binding afﬁnitywith human
PrPC, were obtained from simulations for all compounds in the chemical
compound library. We selected 96 compounds as candidates for anti-
prion agents by analysing docking scores and similarities of chemical
structures. In Fig. 1A, the docking conformations of the 96 selected com-
pounds are shown together with the four amino acid residues (N159,
Q160, K194 andE196),whichwere reported to be important for binding
of GN8 (Ishikawa et al., 2009; Kuwata et al., 2007). A total of 93
Fig. 1. Interaction of candidate compounds by in silico calculation with PrP. (A) Binding conformations of the 96 compounds selected by docking simulation. The red sticks represent
compound conformation and the blue sticks represent the four amino acid residues reported to have a strong interaction with GN8. (B) Direct binding of compounds with PrP23–231.
Sensorgrams of GN8 and NPR-056 for binding with mouse or human PrP23–231. The GN8 concentrations were 0, 0.98, 1.95, 3.91, 7.81, 15.6, 31.3 and 62.5 μM, and the NPR-056
concentrations were 0, 0.2, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 μM (from bottom to top). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the online version of this chapter.)
241D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249
242 D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249
Table 1
The anti-prion effects of NPRs in N2a-FK prion-infected cells (IC50).
Compounds IC50 (μM)a
Statistics
(p value)b
GN8 6.72 ± 1.13 –
NPR-053 7.68 ± 2.64 0.5279
NPR-056 3.72 ± 1.57* 0.0115
NPR-015 4.46 ± 3.43 0.2513
NPR-050 5.94 ± 3.43 0.6796
NPR-065 3.73 ± 2.13* 0.0486
a This anti-prion assay have been at least performed 5 times-trial, independently.
b Statistics have been calculated using student's t-test. ⁎p b 0.05 vs GN8.
243D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249compounds were located near N159 and Q160, but slightly away from
K194 and E196. The other three compounds were located in a position
completely different from the pocket. We investigated whether these
candidate compounds, termed ‘NPR,’ exhibited anti-prion effects.
3.2. Evaluation of binding afﬁnity between PrPC and candidate compounds
using surface plasmon resonance (SPR) analysis
To evaluate the interactions between NPRs and PrPC, we analysed
the direct binding afﬁnity of NPRs to refolded recombinant PrP. High-
throughput screening was used to quantify binding afﬁnity and 10-μM
NPRs were sequentially subjected to SPR analysis using sensor chips
with solid-phase human or mouse PrPC (Biacore™). Results conﬁrmed
that a region within the NPRs had a high-binding ability for human
and mouse PrPC. In particular, the binding response (RU) of NPR-056
was estimated to be at least 3-fold greater than others (Supplementary
Fig. S1). Kinetic analysis, which revealed the sensorgram slopes of NPR-
056, showed that the dose-dependent response was similar to GN8
(positive control). The KD, which shows as dissociation constant, values
of NPR-056 were signiﬁcantly less compared with GN8 (Fig. 1B. and
Supplementary Fig. S2). These results suggest that a useful compound
binding to PrPC was appropriately selected by SPR analysis from
among the putative NPRs compounds which calculated by the Nagasaki
docking system on the DEGIMA supercomputer.
3.3. The reduction of PrPSc in persistently prion-infected cells by candidate
compounds
To examine the effect of NPRs on PrPSc, we performedWestern Blot-
ting (WB) analysis using 10-μMNPR-treated persistently prion-infected
cells. Results conﬁrmed signiﬁcantly reduced PrPSc protein levels in per-
sistently Gerstmann–Sträussler–Scheinker syndrome-derived Fukuoka-
1 prion-infected cells (N2a-FK) that were incubated for 48 h after NPR
treatment compared with cells treated with DMSO (Supplementary
Fig. S3A: NPR-005, - 014, -015, -020, -030, -050, -053, -056 and -065).
TheseNPRs also had a similar effect on scrapie-derived 22L prion-infect-
ed cells (N2a-22L) (Supplementary Fig. S3B). To determine the respec-
tive IC50 concentrations, PrPSc levels in cells treated with NPRs were
reduced in a dose-dependent manner (0.1-, 0.5-, 1-, 5- and 10-μM
NPRs) (Fig. 2A and B) (Supplementary Fig. S4A and B). The effective
concentration for 50% reduction of PrPSc (IC50) in NPR-053, -056, -015,
-050 and -065 were between 3.72 and 7.68 μM. In particular, NPR-056
and -065 resulted in signiﬁcantly lower concentrations compared with
GN8 (Table 1). These results suggest that the candidate NPRs com-
pounds, which were calculated by the docking system and conﬁrmedFig. 2. Dose responses of anti-prion compounds in prion-infected cells. (A) N2a-FK cells were
compounds for 48 h. PrPSc, total PrP and β-actin as loading control were detected by immunob
a percentage of the negative control. Results in the graph present mean ± SD from at least th
plotted using Boltzmann curve ﬁtting. (C) Localisation of PrPSc in 10 μM NPR-053 or−056-
using SAF61 antibody (green) and DAPI (blue), respectively. Cells were visualised by confocalby PrPC-binding afﬁnity, effectively reduced PrPSc in persistently
prion-infected cells in a manner similar to GN8. Intriguingly, the low
PrPC-binding afﬁnity groups (NPR-015, -050 and -065) also exhibited
anti-prion effects, although the detailed mechanisms remain to be
shown. To support these results, we subsequently visualised PrPSc
using immunoﬂuorescence analysis. To selectively detect PrPSc, persis-
tently prion-infected cells were incubated with an anti-PrP monoclonal
antibody following treatment with guanidine thiocyanate to reveal ag-
gregated PrPSc in the cells (Homma et al., 2015; Ishibashi et al., 2015).
Results conﬁrmed signiﬁcant PrPSc reduction in theN2a-FK cells follow-
ing treatmentwithNPR-053 and -056 (Fig. 2C). NPR-015, one of the low
PrPC-binding afﬁnity groups, also resulted in a similar PrPSc reduction in
the cells (Supplementary Fig. S4C).
3.4. Analysis of PrPC–NPR interaction using fragment molecular orbital
calculation
The interaction energies between amino acid residues and NPR-053
and−056 were calculated using the FMOmethod, which used binding
structures from the docking simulation. In Fig. 3, the calculated energies
are provided for residues located within 4.0 Å of the compounds. As a
reference, interaction energies of the four residues that are important
for GN8 binding are also listed. Negative interaction energy represents
an attractive interaction with the compounds. The energies obtained
by the HF method mainly included a polar interaction (i.e., electrostatic
and charge-transfer interaction), which is a major component of a hy-
drogen-bonding interaction. Conversely, the energies obtained using
theMP2method included a van derWaals interaction (or non-polar in-
teraction). Thus, a difference betweenHF andMP2 energies was consid-
ered to be van der Waals energy. Residues with large negative
interaction energy were not found in the HF results, indicating that an
important hydrogen-binding interaction does not exist. Conversely,
MP2 energies of several residues result in a large negative value. These
results suggested that the van der Waals interaction plays a major role
in the binding of NPR-053 and -056 with PrPC.
3.5. Effect of NPRs on stabilising recombinant PrP with thermal changes
Generally, high-throughput screening is performed using the TSA to
determine whether low-molecular-weight ligands, such as chemical
compounds, might interact with target proteins. TSA allows for the
quantiﬁcation of a direct interaction between compounds and progres-
sive protein denaturation. Fluorescence-based TSA (F-TSA) uses a ﬂuo-
rescence dye, such as Sypro® orange, to bind to hydrophobic regions
within the protein; this low-cost, simple and readily measurable meth-
od is widely used to rapidly acquire data. In this study, we examined
whether the compounds were able to interrupt PrPC denaturation de-
pending on incremental temperature increases. Fluorescence intensity
levels of samples containing recombinant PrPC as the substrate were re-
vealed as thermal melting curves, which gradually increased in temper-
ature from 37 °C to approximately 70 °C. Eventually, ﬂuorescence
intensity levels gently became reduced by the time of measurable max-
imum degree (approximately 90 °C), but not no substrate line (Fig. 4).
The protein stability proﬁles of F-TSA following GN8 andNPR treatment
revealed distinctive Tm values that represented responsive degrees to
the maximum value in the ﬁrst derivative curve of the thermal melting
curve. The difference between compound treatment and no treatment
was calculated as ΔTm. NPR-053 treatment revealed a ΔTm oftreated with different concentrations (0, 0.1, 0.5, 1, 5 and 10 μM) of NPR-053 and -056
lotting. (B) PrPSc band intensities treated by individual NPR concentrations are shown as
ree to ﬁve independent experiments. The dose-dependent PrPSc reduction curves were
treated N2a-FK cells using immunoﬂuorescent staining. PrPSc and nuclei were detected
laser-scanning microscopy. Scale bars represent 10 μm.
244 D. Ishibashi et al. / EBioMedicine 9 (2016) 238–2492.692 ± 0.189 degrees, which was signiﬁcantly greater than with GN8
treatment, suggesting that NPR-053 might stabilise PrPC by binding to
PrPC. These results were not observed with NPR-056 (Table 2). To con-
ﬁrm the effect of NPRs on PrPC expression and cellular cytotoxicity, we
treated mouse neuroblastoma cells overexpressing PrPC (N2a-58)
with different concentrations of NPR-015,−053 and −056 for 48 h,
and determined PrPC levels and cell viability. Results showed that
none of the NPRs inﬂuenced PrPC levels and cell viability in the N2a-
58 cells (Supplementary Fig. S5).Fig. 3. Interaction energy of each amino acid residue with NPR-053 and -056. (A) Energ
Interaction energies of residues located within 4.0 Å are provided. Electrostatic and charge-tr
MP2 (red). (B) Binding conformation of NPR-053 and -056 were obtained from docking simu
large interaction energy with the compound are represented by a stick model. For the purpos
(orange).3.6. Bioassay using prion disease model mice treated by NPRs
To elucidate whether the NPRs were effective in animal models of
prion diseases, CD-1mice inoculatedwith Fukuoka-1 brain homogenate
were administered either NPR-053 or NPR-056 three times in a week
from 2 days post-inoculation (d.p.i.) until sacriﬁce. We analysed PrPSc
and histological changes in the brains of mice at 110 d.p.i., which was
the time point at which the mice developed symptoms. PrPSc levels in
the NPR-treated brains were 20–30% less than in the vehicle-treatedies between amino acid residues and NPRs were calculated using the FMO method.
ansfer interactions caluculated by the HF (blue); van der Waals interaction calculated by
lation. Human PrPC (white tube) and compounds (red stick). Several residues exhibiting
e of reference, positions of the four residues largely interacting with GN8 are represented
Table 2
The effects of NPRs against recombinant prion protein stability using ﬂuorescence-based
thermal shift assay.
Compounds ΔTm (°C)a
Statistics
(p value)b
GN8 0.680 ± 1.037 0.3198
NPR-053 2.692 ± 0.189 1.596E−05
NPR-056 −0.005 ± 0.631 0.9907
a The F-TSA have been at least performed 3 times-trial, independently. Melting tem-
perature (Tm) values indicate maximum responsive value in ﬁrst derivative curve from
the thermal melting curve. Each ΔTm value shows difference of respective samples com-
pared with no-compound.
b Statistics have been calculated using student's t-test. ⁎⁎⁎p b 0.001 vswithout
compound.
Fig. 4. Recombinant PrP stabilisation by NPRs using ﬂuorescence-based thermal shift assay. The temperature-dependent recombinant PrP denaturation proﬁle shows a two-phase
transition. PrP-binding afﬁnity of several compounds can be assessed from the shift of unfolding temperature to easily obtain potential compounds with a stabilising inﬂuence on PrP.
Recombinant PrP was analysed by F-TSA in the presence of 0.5% DMSO, 10 μM GN8, NPRs, or buffer only (no PrP). Figures show each representative denaturation proﬁle, respectively.
Solid lines: no compounds (PrP only), grey lines: buffer only.
245D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249brains at disease onset (Fig. 5A). NPR-056 treatment signiﬁcantly re-
duced the vacuolar area in the cortex comparedwith vehicle treatment.
However, NPR-053 treatment resulted in no obvious changes in the cor-
tex (Fig. 5B). We also evaluated gliosis levels in the brains of NPR-treat-
ed mice at onset. At 110 d.p.i., NPR-056 treatment signiﬁcantly reduced
expression of Iba-1 protein (also known as allograft inﬂammatory factor
1: AIF1), which is an EF-hand protein and amarker of activatedmicrog-
lia (Ito et al., 1998; Sakai et al., 2013) (Fig. 5C). Immunohistochemical
staining revealed that the area occupied by Iba-1-positive cells was sig-
niﬁcantly decreased in the cortex, thalamus and hippocampus (Fig. 5D).
However, the survival periods of the treated groups remained un-
changed compared with the mice treated with vehicle (Supplementary
Fig. S6). These results showed that NPR-056 inhibited PrPSc accumula-
tion and the associated pathological changes, including neuronal cell
death and microgliosis, suggesting that this compound could serve as
a candidate drug for prion diseases.
3.7. NPR effect on aggresomes in N2a-FK cells
Aggresomes are established by the aggregation of a variety of ines-
sential proteins and intracellular inclusion bodies co-localising with
the accumulation of phosphorylated tau and alpha-synuclein in patho-
logical tissues and cell culture models of conformational diseases
(Kothawala et al., 2012; Shen et al., 2011). Aggresomes are large com-
plexes of aberrant proteins that exhibit resistance to degradation and
are, therefore, sequestered as inclusion bodies. It is thought that seques-
trated aggresomes can be degraded by the autophagy system (Doi et al.,
2013; Matsumoto et al., 2011; Watanabe et al., 2012). Recent reports
have shown that aggresomes containing p62 and PrPSc form in persis-
tently prion-infected cells; p62 interacts closelywith PrPSc and is critical
in promoting degradation via the autophagy system (Homma et al.,
2014b).
In this study, we used the aggresome detection probe as Proteostat
to determine whether NPRs affect aggresome levels in persistently
prion-infected cells. Many aggresomes were detected in the cytoplasm
of N2a-FK cells treated by DMSO only. The anti-prion compounds thatwere shown to suppress PrPSc (GN8, NPR-015, -053 and -056) also sig-
niﬁcantly reduced the number of intracellular aggresomes in the N2a-
FK cells after treatment for 48 h with 10 μM of the compounds, respec-
tively (Fig. 6). These results indicated that NPRs might facilitate clear-
ance of PrPSc, as well as dysfunctional and unnecessary proteins in the
cytoplasm.
4. Discussion
In the search for drugs for human prion diseases, we conducted
docking simulation using a DEGIMA supercomputer. Results from the
in vitro and ex vivo drug screening revealed that NPR-053 and -056 sig-
niﬁcantly reduced PrPSc levels (Figs. 2 and 5). Although the afﬁnity of
NPR-056 for PrPCwas approximately 2-fold greater than NPR-053 (Sup-
plementary Fig. S1), thermal stabilisation of the NPR-053–PrPC complex
was signiﬁcantly stronger than the GN8–PrPC complex (Fig. 4 and Table
2), indicating that bonding varies among NPRs. Intriguingly, although
NPR-015 and -065 did not bind with PrPC in the SPR assay, all NPRs (-
015, -050, -053, -056 and -065) exhibited anti-prion effects in FK-1
and 22L strains (Supplementary Fig. S3B). These results suggested that
NPRs might exhibit suppressant effects against PrPSc in universal prion
strains depending on the binding of NPRs to PrPC, although these results
Fig. 5.NPR-053 and -056 suppress PrPSc, vacuolation andmicrogliosis inmouse brains at 110 d.p.i. (A)Micewere sacriﬁced at 110 d.p.i. and PrPSc levelsweremeasured in the brains. PrPSc
accumulation (band intensity) was analysed bywestern blotting usingM20 antibody as a primary antibody. (B) Degree of vacuolation changewas compared by HE staining. The vacuole-
occupied area in each sectionwas calculated. (C) Iba-1 expression in themouse brainswas analysed bywestern blotting and immunohistochemical staining. The ratio of Iba-1/β-actinwas
calculated from band intensities by western blotting. (D) Microglial activation was analysed by quantifying Iba-1-positive cells following immunohistochemistry. In all bar graphs, white,
grey and black bars represent vehicle, NPR-053 and−056 groups, respectively. In histological analysis, all scale bars represent 50 μm. Statistical signiﬁcances in immunoblotting were
determined using the two-tailed Student's t-test, and two-way analysis of variance followed by the Tukey–Kramer test for multiple comparisons was used for histological analysis in
brain regions (cortex: Co, thalamus: Th, hippocampus: Hi, putamen: Pu and pons: Po). *p b 0.05 and **p b 0.01.
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Fig. 6. Aggresome detection in prion-infected cells after NPR treatment. N2a-FK cells treated with 10 μM GN8, NPR-015, -053, or -056 compounds for 48 h were subjected to protein
aggregation assays. Aggresomes in cells were detected using ProteoStat® (red). Cell nuclei were counterstained with Hoechst 33342 (blue). Cells were visualised by confocal laser-
scanning microscopy, and whole cells were visualised by differential interference contrast (DIC) with transmitted light. Scale bars represent 10 μm.
247D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249differed from drugs with a strain-dependent function such as Cpd B
(Kawasaki et al., 2007). Conversely, NPRs had no effect on PrPC levels
and cellular toxicity (Supplementary Fig. S5), suggesting that NPRs do
not promote PrPC degradation, compared with activation of the ubiqui-
tin–proteasome system by IU-1 (Homma et al., 2015) and
macroautophagy by lithium (Heiseke et al., 2009) and FK506
(Nakagaki et al., 2013). Results from the bioassay showed that NPR-
053 and -056 treatments markedly suppressed PrPSc and gliosis levels
in the brains of mice at onset, but had no effect on survival (Fig. 5 and
Supplementary Fig. S6), indicating that the effective drugs which is
left in brain after NPR-treatmentmight be very low levels. The pharma-
cokinetics, such as transportation to the brain and drug stabilisation, re-
mains poorly understood, so future studies should focus on the routes,
periods, frequency and dosages of NPRs.
The intracellular aggregations of dysfunctional misfolded proteins
are removed by a variety of homeostatic mechanisms, including endo-
plasmic reticulum-associated degradation, the ubiquitin–proteasome
system and the autophagy system. PrPSc has been shown to co-localise
with p62 and form aggresomes in prion-infected cells (Homma et al.,
2014b). Intriguingly, results from this study shown that some NPRs sig-
niﬁcantly reduced the development of aggresomes (Fig. 6). Previous re-
ports have shown that aggresomes are degraded by a selective
autophagy system that recognises LC3-tagged protein complexes
(Bjorkoy et al., 2005; Ichimura et al., 2008; Komatsu et al., 2007;Pankiv et al., 2007). The location of senile plaques in theAlzheimer's dis-
ease brain, which is the result of Aβ and neuroﬁbrillary tangles caused
by hyper-phosphorylated tau and inclusion bodies, which are formed
by alpha-synuclein in Parkinson's disease cell culture models, is identi-
cal to the location of aggresomes (Kothawala et al., 2012; Shen et al.,
2011). These results suggest that NPRs could protect against prion dis-
ease as well as other conformational diseases that accumulate
aggresomes.
Molecular simulation and analysis of atomic level interactions be-
tween NPRs and PrPC showed that the binding sites of NPR-053 and -
056 were located around the four amino acid residues — N159, Q160,
K194 and E196 (Fig. 1A). High-pressure NMR shows that this position
is less stable (Kuwata et al., 2002) and is considered to be a “hot spot”
for the pathogenic conversion of prion diseases (Kuwata et al., 2007;
Yamamoto, 2014). Indeed, GN8 can stabilise PrPC and inhibit conversion
by binding to this position (Ishikawa et al., 2009; Kuwata et al., 2007).
Furthermore, several different structure compounds were reported,
which have anti-prion activity by binding to the similar position
(Ferreira et al., 2014). Our simulation results show that the overall bind-
ing characters of our compounds are consistent with these previous
studies, suggesting that the hydrophobic pocket might be important
for binding of other anti-prion compounds with heterogeneous PrP.
However, the FMO calculations clearly demonstrate that the detailed in-
teraction mechanisms of NPR-053 and -056 are different than GN8. In
248 D. Ishibashi et al. / EBioMedicine 9 (2016) 238–249the case of GN8, polar interactions, including hydrogen-bonding inter-
actions with N159, Q160, K194 and E196 were critical (Ishikawa et al.,
2009). Conversely, HF level calculations revealed no large negative in-
teraction energy (Fig. 3A), suggesting that polar interactions are not im-
portant for the binding of NPR-053 and -056. Instead, MP2 energies of
several residueswere negatively large, indicating that van derWaals in-
teractions play an important role in complex stability. In particular,
G124, L125, Y162, Q186 and H187 exhibit key interactions with the
compounds. The docking structures of NPR-053 and -056 are shown
in Fig. 3B. We note that the aromatic rings of these compounds are in
contact with the amino acid residues, which are capable of generating
a large attractive interaction with PrPC. Thus, our analysis of interaction
energies using the FMOmethodwas consistentwith binding conforma-
tions from the docking simulation.
It must be taken into account that the compounds may also interact
with the ﬂexible N-terminal domain because NPRs have been derived
by molecular simulation from human PrP (124–230 a.a.). To address
this point, an in vitro-binding experiment (i.e. SPR) with puriﬁed PrPs
(121–231 and 90–231 a.a.) will be needed. In addition, interaction
with abnormal form is also another possible action of anti-prion drugs
andwe cannot exclude this possibility regardingwith the NPRs. Contin-
uously, conformation of ﬁbril formed PrP has been analysed using solid-
state NMR, X-ray ﬁber diffraction, Hydrogen exchange mass spectrom-
etry or electron micrograph with high resolution (Laws et al., 2001;
Helmus et al., 2008; Wille et al., 2009; Damo et al., 2010; Smirnovas et
al., 2011), thereby high content of beta sheet and their stacking struc-
ture were suggested (Wille et al., 2002; Groveman et al., 2014). Howev-
er, there are still some obligations to overcome before using the
structural information in docking simulation on DEGIMA at present, be-
cause some of them are hypothetical and not sufﬁcient. In the future,
speciﬁc anti-prion drugs that can directly interact with abnormal PrP
structure will be necessary for treatment of prion disease, because nor-
mal cellular PrP has a critical physiological function on maintenance of
myelin and axon (Bremer et al., 2010).
In conclusion, results from in silico screening and targeting of the
PrPC structure showed that this method could be useful for drug discov-
ery against prion disease. Future studies should evaluate these effects in
animal models of disease, in in vitro screening with post-translational
modiﬁcations of PrPC and in the structure analysis using NMR of the
compounds–PrPC complexes. Results also showed that NPRs could be
made widely available as candidate drugs for conformational disease.
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